Alkermes plc Reports Financial Results for the Fourth Quarte

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

-- Revenues of $1.17 Billion in 2021, GAAP Loss per Share of $0.30 and Diluted Non-GAAP Earnings per Share of $0.78 -- -- Financial Expectations for 2022 and Updated Long-Term Profitability

Related Keywords

United States , Massachusetts , Athlone , Westmeath , Ireland , Ohio , Waltham , Dublin , Kenilworth , American , Katie Joyce , Iain Brown , Catot Laurencin , Sandy Coombs , Janssen Pharmaceutica , American Society Of Clinical Oncology , Psych Congress , Rodin Therapeutics Inc , Neuroscience Education Institute , Nasdaq , Merck Co Inc , Johnson Company , Alkermes Inc , International Society For Affective Disorders , Alkermes , Society For Immunotherapy Of Cancer , Drug Administration , Development Revenues , Merck Sharp Dohme Corp , Exchange Commission , Biogen Ma Inc , Alkermes Pharma Ireland , Proprietary Products , Continued Operating , Richard Pops , Chief Executive Officer , Goods Manufactured , Rodin Therapeutics , Chief Financial Officer , International Society , Affective Disorders , American Society , Clinical Oncology , Cancers Symposium , Sarissa Capital Management , Private Securities Litigation Reform Act , Annual Report , Alkermes Pharma Ireland Limited , Merck Sharp , Dohme Corp , Additional Information , General Meeting , Information Regarding Participants , Current Reports , Initial Statements , Beneficial Ownership , Financial Information , Consolidated Statements , Per Share , Average Number , Ordinary Shares Outstanding , Earnings Per Share , Calendar Year , Net Loss , Reports , Financial , Results , Fourth , Quarter , Ear , Nded , 021 , Rovides , Expectations , 022 ,

© 2025 Vimarsana